Alok A. Khorana, MD

Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Cleveland, Ohio

Dr. Alok Khorana received his medical degree from Maharaja Sayajirao University’s Medical College in Baroda (Gujarat), India. His postdoctoral training included a residency in internal medicine at the University at Buffalo in New York and a fellowship in hematology/oncology at the University of Rochester, New York. He is a Fellow of the American College of Physicians. Dr. Khorana is Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, the Sondra and Stephen Hardis Chair in Oncology Research, Vice-Chair for Clinical Services and Strategy of the Taussig Cancer Institute, and Director of the Gastrointestinal Malignancies Program at the Cleveland Clinic, Cleveland, Ohio.

Dr. Khorana is past chair of the American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines Panel (CPGC), chair of ASCO CPGC’s Pancreas Cancer Working Group, and co-chair of the ASCO Guidelines Panel on Resectable Pancreas Cancer. He also serves on the ASCO Scientific Program Committee and multiple ASCO guideline panels. He is past chair of the International Society on Thrombosis and Haemostasis Scientific Subcommittee on Hemostasis and Malignancy. In addition, he has previously served as a member of the US Pharmacopoeia Oncology Expert Committee. Dr. Khorana has been published in a variety of journals including New England Journal of Medicine, Journal of American Medical Association (JAMA), Journal of Clinical Oncology, Blood, Journal of the National Cancer Institute, Clinical Cancer Research, PLoS One, and JAMA Internal Medicine.He has co-authored chapters in multiple textbooks including Cecil Essentials of Medicine and DeVita’s Cancer: Principles and Practice of Oncology, and isco-editor of the book Cancer-Associated Thrombosis: New Findings in Translational Science, Prevention and Treatment.

Dr. Khorana’s clinical and translational research programs focus on predictive factors and drug development in gastrointestinal cancers and cancer-associated thrombosis and has been funded by grants from the National Cancer Institute, the National Heart, Lung, and Blood Institute, the Porter Family Fund, the Scott Hamilton CARES Initiative, and the V Foundation.

Last modified: October 20, 2017

Partners in Pancreatic Cancer would like to recognize and thank Celgene Corporation
for their educational support of PartnersinPancreaticCancer.com.

©2017 MediCom Worldwide, Inc. All rights reserved